
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is a profitable biotechnology company focused on delivering a broad slate of best-in-class eye-care products to the US market. With a portfolio of 18 branded ophthalmic pharmaceuticals and a strong focus on commercialization and acquisition, the company is well-positioned for growth. The recent hiring of a sales force specifically targeting the drug VEVYE, along with upcoming clinical data for IHEEZO in the intravitreal injection space, are expected to be key catalysts for future growth. With a strong management team and a clear focus on driving sales, Harrow appears poised for continued success.
Bears say
Harrow is facing several fundamental challenges that may hinder its growth and profitability. One of the main concerns is its reliance on the MELT franchise, which is not included in its latest guidance. The company's history of operating losses, regulatory risks, potential need for additional funding, and intense competition also contribute to a negative outlook. Additionally, the success of its assets, such as Iheezo and QUELL, is integral to its future profitability and any delays or difficulties in their adoption could significantly impact Harrow's valuation.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares